Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · IEX Real-Time Price · USD
0.397
-0.006 (-1.49%)
Jul 22, 2024, 9:31 AM EDT - Market open
Sangamo Therapeutics Employees
Sangamo Therapeutics had 405 employees as of December 31, 2023. The number of employees decreased by 73 or -15.27% compared to the previous year.
Employees
405
Change (1Y)
-73
Growth (1Y)
-15.27%
Revenue / Employee
$46,311
Profits / Employee
-$810,007
Market Cap
82.40M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
CASI Pharmaceuticals | 176 |
AlloVir | 112 |
DBV Technologies | 105 |
Verastem | 73 |
BioAtla | 65 |
AN2 Therapeutics | 41 |
Benitec Biopharma | 18 |
Genenta Science | 14 |
SGMO News
- 2 months ago - Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results - Business Wire
- 2 months ago - Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing - Business Wire
- 2 months ago - Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast - Business Wire
- 3 months ago - Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) - Business Wire
- 4 months ago - Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering - Business Wire
- 4 months ago - Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results - Business Wire
- 4 months ago - Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs - Business Wire
- 4 months ago - Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast - Business Wire